WMP operates by reducing the levels of TLR4 and TRAF6 proteins, thereby suppressing immune hyperactivity in RA, ultimately impeding the nuclear translocation of NF-κB and IκB-α phosphorylation, thus curtailing the production of inflammatory cytokines (e.g., TNF and IL-6) in RA-α. The gene discussed is TRAF6; the disease is rheumatoid arthritis.